Abstract
A 49-year-old woman developed new-onset type 1 diabetes after initiating Wegovy (semaglutide) via an online clinic, without prior screening. She experienced rapid weight loss and hyperglycemia symptoms. Blood tests indicated high GAD65 and low C-peptide. The case underscores the need for biochemical screening and follow-up in digital obesity care.
| Bidragets oversatte titel | Onset of type 1 diabetes after treatment with online-prescribed semaglutide |
|---|---|
| Originalsprog | Dansk |
| Artikelnummer | V06250507 |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 188 |
| Udgave nummer | 8 |
| ISSN | 0041-5782 |
| DOI | |
| Status | Udgivet - 16 feb. 2026 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Debut af type 1-diabetes efter behandling med onlineordineret semaglutid'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS